COL1A2-related Ehlers-Danlos syndrome

disease
On this page

Summary

COL1A2-related Ehlers-Danlos syndrome (MONDO:0100606) is a disease caused by COL1A2 (GenCC Definitive), with 1 cohort gene.

At a glance

  • Causal gene: COL1A2 (GenCC Definitive)
  • Cohort genes: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameCOL1A2-related Ehlers-Danlos syndrome
Mondo IDMONDO:0100606
GARD0027289
Is cancer (heuristic)no

Data availability: 1 GenCC gene-disease record.

Disease family

An umbrella term covering 3 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › syndromic diseaseEhlers-Danlos syndromeCOL1A2-related Ehlers-Danlos syndrome

Related subtypes (24): Ehlers-Danlos syndrome, classic type, Ehlers-Danlos syndrome, hypermobility type, Ehlers-Danlos syndrome, arthrochalasia type, Ehlers-Danlos syndrome, spondylodysplastic type, Ehlers-Danlos syndrome, periodontitis type, Ehlers-Danlos syndrome, autosomal dominant, type unspecified, joint laxity, familial, Ehlers-Danlos syndrome, fibronectinemic type, Ehlers-Danlos syndrome, dermatosparaxis type, brittle cornea syndrome, X-linked Ehlers-Danlos syndrome, Ehlers-Danlos syndrome, musculocontractural type, Ehlers-Danlos syndrome due to tenascin-X deficiency, Ehlers-Danlos syndrome, Beasley-Cohen type, Ehlers-Danlos syndrome, kyphoscoliotic type, 2, Ehlers-Danlos syndrome, kyphoscoliotic type 1, Ehlers-Danlos syndrome, vascular-like type, Ehlers-Danlos/osteogenesis imperfecta syndrome, Ehlers-Danlos syndrome, vascular type, spondylodysplastic Ehlers-Danlos syndrome, Bethlem myopathy 2, Ehlers-Danlos syndrome, classic-like, 2, COL1A1-related Ehlers-Danlos syndrome, Ehlers-Danlos syndrome, classic-like, 3

Subtypes (3): Ehlers-Danlos syndrome, cardiac valvular type, combined osteogenesis imperfecta and Ehlers-Danlos syndrome 2, Ehlers-Danlos syndrome, arthrochalasia type, 2

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 21 · Orphanet: 8 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

GeneClassificationInheritanceDiseaseRecords
COL1A2DefinitiveAutosomal recessiveEhlers-Danlos syndrome, cardiac valvular type21

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
COL1A2Orphanet:1899Arthrochalasia Ehlers-Danlos syndrome
COL1A2Orphanet:216796Osteogenesis imperfecta type 1
COL1A2Orphanet:216804Osteogenesis imperfecta type 2
COL1A2Orphanet:216812Osteogenesis imperfecta type 3
COL1A2Orphanet:216820Osteogenesis imperfecta type 4
COL1A2Orphanet:230851Cardiac-valvular Ehlers-Danlos syndrome
COL1A2Orphanet:230857Ehlers-Danlos/osteogenesis imperfecta syndrome
COL1A2Orphanet:314029High bone mass osteogenesis imperfecta

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence1

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
COL1A2HGNC:2198ENSG00000164692P08123Collagen alpha-2(I) chaingencc

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
COL1A2Collagen alpha-2(I) chainType I collagen is a member of group I collagen (fibrillar forming collagen).

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Other/Unknown11.8×0.558

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
COL1A2Other/UnknownnoFib_collagen_C, Collagen, Collagen_superfamily

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)1
unknown0

Top tissues across cohort

TissueCohort genes
periodontal ligament1
skin of hip1
stromal cell of endometrium1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
COL1A2295ubiquitousmarkerperiodontal ligament, stromal cell of endometrium, skin of hip

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
COL1A2179

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
COL1A2P081235

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 27. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Defective VWF binding to collagen type I13806.7×0.003COL1A2
Enhanced cleavage of VWF variant by ADAMTS1312855.0×0.003COL1A2
Defective VWF cleavage by ADAMTS13 variant12855.0×0.003COL1A2
Enhanced binding of GP1BA variant to VWF multimer:collagen11631.4×0.003COL1A2
Defective binding of VWF variant to GPIb:IX:V11631.4×0.003COL1A2
GP1b-IX-V activation signalling1951.7×0.004COL1A2
Anchoring fibril formation1761.3×0.004COL1A2
Platelet Adhesion to exposed collagen1671.8×0.004COL1A2
Scavenging by Class A Receptors1601.0×0.004COL1A2
Fibronectin matrix formation1571.0×0.004COL1A2
Crosslinking of collagen fibrils1571.0×0.004COL1A2
Platelet Aggregation (Plug Formation)1439.2×0.005COL1A2
Syndecan interactions1423.0×0.005COL1A2
MET activates PTK2 signaling1380.7×0.005COL1A2
GPVI-mediated activation cascade1308.6×0.005COL1A2
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription1308.6×0.005COL1A2
Collagen chain trimerization1259.6×0.006COL1A2
Developmental Lineage of Pancreatic Ductal Cells1228.4×0.007COL1A2
Assembly of collagen fibrils and other multimeric structures1200.3×0.007COL1A2
Collagen degradation1175.7×0.008COL1A2
Collagen biosynthesis and modifying enzymes1170.4×0.008COL1A2
Non-integrin membrane-ECM interactions1154.3×0.008COL1A2
ECM proteoglycans1150.3×0.008COL1A2
Integrin cell surface interactions1134.3×0.008COL1A2
Interleukin-4 and Interleukin-13 signaling1102.9×0.010COL1A2
Cell surface interactions at the vascular wall195.2×0.011COL1A2
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell187.2×0.011COL1A2

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
protein heterotrimerization116852.0×8e-04COL1A2
skin morphogenesis11404.3×0.003COL1A2
collagen metabolic process11053.2×0.003COL1A2
extracellular matrix assembly1936.2×0.003COL1A2
odontogenesis1526.6×0.005COL1A2
blood vessel development1374.5×0.005COL1A2
cellular response to amino acid stimulus1306.4×0.005COL1A2
bone mineralization1271.8×0.005COL1A2
Rho protein signal transduction1247.8×0.005COL1A2
collagen fibril organization1224.7×0.005COL1A2
regulation of blood pressure1221.7×0.005COL1A2
transforming growth factor beta receptor signaling pathway1159.0×0.007COL1A2
skeletal system development1125.8×0.008COL1A2

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
COL1A200

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

SymbolAssaysType breakdown
COL1A24Functional:4

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug1COL1A2

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
COL1A24

Clinical trials & evidence

Clinical trials

Clinical trials: 0.